Furginum Hasco is recommended for use for the treatment of acute and recurrent low urinary tract infections. He is pre -escorted for people over 15 years of age.

Furginum Hasco is a preparation whose active substance is furazidine. Furazidine, a derivative of nitrofuran, inhibit the development of bacteria that are responsible for causing urinary tract infection. It affects both gram-positive and gram-negative bacteria and is well absorbed from the digestive tract. The preparation tolerates unpleasant symptoms of infection, such as unpleasant baking when urinating or soreness.

Active substance: Furazidine (Furazidinum), also called furagine

1 tablet contains 50 mg furazidine.

Other ingredients (auxiliary substances): gelled, corn starch, sucrose, colloidal flip -free silica, stearic acid 50

Furginum Hasco should be taken orally during protein -containing meals, which increases the absorption of the preparation.

Light and youth after the age of 15:

First day of treatment: 100 mg (2 tablets) 4 times a day; Next days: 100 mg (2 tablets) 3 times a day.

The dividing line makes it easier to break the tablet to swallow easier and is not used to divide the tablet into two equal doses.

The preparation is used for 7-10 days.

If the symptoms get worse or fail during this period, please contact your doctor.

Furginum Hasco should not be used:

- if the patient is allergic to furazidine, nitrofuran derivatives or any of the other ingredients of this preparation;

- in the first three months of pregnancy;

- during the period of pregnancy (from the 38th week) and delivery, due to the risk of a newborn baby of hemolytic anemia (anemia associated with the breakdown of red blood cells);

- in children and adolescents under the age of 15;

- if the patient has had kidney failure (creatinine clearance below 60 ml/min or elevated serum creatinine in laboratory tests);

- if the patient was diagnosed with polyneuropathy (nervous system disorder associated with peripheral nerve damage, which may have physical or sensory disorders), e.g. in the course of diabetes;

-if the patient has a deficiency of the enzyme of glucose-6-phosphate dehydrogenase (the enzyme involved in the transformations occurring in red blood cells).